

CITATION REPORT

List of articles citing

Expanding the Treatment Landscape for Lennox-Gastaut Syndrome: Current and Future Strategies

DOI: 10.1007/s40263-020-00784-8
CNS Drugs, 2021, 35, 61-83.

Source: <https://exaly.com/paper-pdf/82928331/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Prescription patterns of antiseizure drugs in tuberous sclerosis complex (TSC)-associated epilepsy: a multicenter cohort study from Germany and review of the literature. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 749-760	3.8	6
19	The unchanging face of Lennox-Gastaut syndrome in adulthood. <i>Epilepsy Research</i> , 2021 , 172, 106575	3	
18	Clinical Trial Outcome Measurements in Lennox-Gastaut Syndrome and Their Application to the Development of Targeted Treatments. <i>Current Treatment Options in Neurology</i> , 2021 , 23, 1	4.4	
17	Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 91, 296-307	3.2	3
16	Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211031100	6.6	3
15	GABAkines - Advances in the discovery, development, and commercialization of positive allosteric modulators of GABA receptors. <i>Pharmacology & Therapeutics</i> , 2021 , 108035	13.9	1
14	The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders.. <i>Pharmacology Biochemistry and Behavior</i> , 2022 , 213, 173321	3.9	2
13	Are anti-seizure medications effective and safe treatments for Lennox-Gastaut syndrome? A Cochrane Review summary with commentary.. <i>Developmental Medicine and Child Neurology</i> , 2022 ,	3.3	
12	Anticonvulsant Agents: Cannabidiol and Fenfluramine. 2022 , 1-15		0
11	Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine. <i>Frontiers in Pharmacology</i> , 2022 , 13,	5.6	0
10	Cannabidiol Successful Therapy for Developmental and Epileptic Encephalopathy Related to CYFIP2. <i>The Open Neurology Journal</i> , 2022 , 16,	0.4	0
9	An Italian consensus on the management of Lennox-Gastaut syndrome. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2022 ,	3.2	0
8	A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). <i>Epilepsia</i> ,	6.4	2
7	Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies.		3
6	Diagnostics and age-related evolution of Lennox-Gastaut syndrome. Management in diverse patient age periods. 2022 , 14, 276-293		0
5	Anti-convulsant Agents: Cannabidiol and Fenfluramine. 2022 , 3781-3795		0
4	Treatment with Cenobamate in Adult Patients with Lennox-Gastaut Syndrome: A Case Series. 2023 , 12, 129		0

- 3 Bewährtes und Neues in der medikamentösen Epilepsitherapie. **2023**, 35, 30-33
- 2 Pediatric epilepsy surgery in patients with Lennox-Gastaut syndrome after viral encephalitis. 14,
- 1 The burden of illness in Lennox-Gastaut syndrome: a systematic literature review. **2023**, 18,